NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluati
Regional activation for Nanobiotix pivotal Phase 3 trial in head and neck cancer proceeds as planned with first patient enrolled in Asia by partner LianBioThe collaboration continues to build momentum behind LianBio’s leadership in Asia while Nanobiotix remains focused on enrollment globallyPARIS & CAMBRIDGE, Mass....
Source: pharmiweb.com